What are your questions? It was clear from the report that they are being careful on any generic involvement next year. The street doesn't like uncertainity. We learned that with vidaza survival impact. I sold my IRA shares. Knowing that I could buy them back at a lower price. This way I get not taxes and maybe 500+ shares.
This doesn't change the long term picture. Because we need sgi-110 to replace dacogen. I plan on owning my shares back before the conference in Dec. I may buy additional shares if it gets to my lower range.
What is the status of AT7519? No update was given yesterday.
2. Did Astex sell its entire position in SRPT and if so, at what price? I see a gain on investments for the quarter and assume it is from selling SRPT.
3. There was an impairement charge of $7.4M in the quarter. Do we anticipate another this year or 2013? I believe this is from the Astex Thera transaction.
4. Are we still scheduled for the Phase 2 data updates in Q4 for SGI-110 in AML/MDs and preliminary Phase 2 data in GIST realted to AT13387? Are we waiting for any other data readouts this quarter?
5. I understand that Dacogen is going off patent in 2013 but not sure why managment thinks sales will go down considering that when Vidaza when off patent in 2011 there has been no effect on sales. As a matter of fact, sales for Dacogen and Vidaza are up since Vidaza went off patent. Are you seeing a generic competitor in the horizon?